Orexo signs up Invida for Abstral in Asia Pacific
This article was originally published in Scrip
Orexo, the Swedish specialty pharma company focusing on pain management and inflammation, has granted Invida Group an exclusive licence covering the Asia Pacific region for Abstral (fentanyl citrate) breakthrough cancer pain treatment. The deal almost completes global coverage for the product. Indeed, the Swedish company is now looking for a partner to take up rights to the drug for the Latin American markets.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.